Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
# Robots.txt file from http://www.arkaytherapeutics.com Sitemap: http://www.arkaytherapeutics.com/sitemap.xml User-agent: * |
Title | Type 2 diabetes Company, novel beta cell centric product ARKAY |
Description | TriGlytza™: A Patient-Centric Think-Outside-The-Box Approach For Treating Type 2 (609) 362-6818 Follow Us: Home Our Approach Investors Our Team News Career Publications Contact Forefront of Modern Innovative Medicine --> --> --&g |
Keywords | N/A |
WebSite | arkaytherapeutics.com |
Host IP | 206.188.192.1 |
Location | United States |
Site | Rank |
US$2,632,438
Last updated: 2023-05-13 00:50:19
arkaytherapeutics.com has Semrush global rank of 4,020,724. arkaytherapeutics.com has an estimated worth of US$ 2,632,438, based on its estimated Ads revenue. arkaytherapeutics.com receives approximately 303,743 unique visitors each day. Its web server is located in United States, with IP address 206.188.192.1. According to SiteAdvisor, arkaytherapeutics.com is safe to visit. |
Purchase/Sale Value | US$2,632,438 |
Daily Ads Revenue | US$2,430 |
Monthly Ads Revenue | US$72,899 |
Yearly Ads Revenue | US$874,780 |
Daily Unique Visitors | 20,250 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
arkaytherapeutics.com. | A | 7200 | IP: 206.188.192.1 |
arkaytherapeutics.com. | NS | 7200 | NS Record: ns64.worldnic.com. |
arkaytherapeutics.com. | NS | 7200 | NS Record: ns63.worldnic.com. |
arkaytherapeutics.com. | MX | 7200 | MX Record: 10 mx.myregisteredsite.com. |
arkaytherapeutics.com. | TXT | 7200 | TXT Record: v=spf1 include:spf.registeredsite.com ~all |
(609) 362-6818 Follow Us: Home Our Approach Investors Our Team News Career Publications Contact Forefront of Modern Innovative Medicine --> --> --> --> --> Human proof-of-concept (PoC): Immunofluorescence with Cox-2 (red) and DAPI (blue). Cox-2 is elevated in pancreatic islets of Type 2 diabetes (T2DM) patients compared to human islets isolated from patients without T2DM (ND). Mission Statement Change The Current Type 2 Diabetes Disease Trajectory of Failure Of First, Second And Third Line of Therapies, Clinical Inertia, Insulin Dependence and Diabetes Complications Recent Press Releases February 20, 2019 | ARKAY Therapeutics Announced as a Finalist in Most Successful Early Phase Research in 2019 Clinical & Research Excellence Awards June 5, 2018 | The U.S. FDA Approves ARKAY Therapeutics’ IND Application for Evaluating RK-01, a First-in-Class ‘Beta-cell-centric’ Drug Combination Product in Type 2 Diabetes Patients Click to Enlarge TriGlytza™: A Patient-Centric |
HTTP/1.1 301 Moved Permanently Server: openresty/1.19.9.1 Date: Mon, 20 Dec 2021 09:09:39 GMT Content-Type: text/html; charset=iso-8859-1 Content-Length: 241 Connection: keep-alive Location: http://www.arkaytherapeutics.com/ X-Webcom-Cache-Status: BYPASS HTTP/1.1 200 OK Server: openresty/1.19.9.1 Date: Mon, 20 Dec 2021 09:09:40 GMT Content-Type: text/html Content-Length: 176348 Connection: keep-alive Vary: Accept-Encoding Last-Modified: Mon, 18 Oct 2021 19:12:18 GMT ETag: "2b0dc-5cea552d34b6e" X-Webcom-Cache-Status: BYPASS Accept-Ranges: bytes |
Domain Name: ARKAYTHERAPEUTICS.COM Registry Domain ID: 1869670547_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.networksolutions.com Registrar URL: http://networksolutions.com Updated Date: 2021-06-05T09:05:59Z Creation Date: 2014-08-04T18:57:41Z Registry Expiry Date: 2022-08-04T18:57:41Z Registrar: Network Solutions, LLC Registrar IANA ID: 2 Registrar Abuse Contact Email: abuse@web.com Registrar Abuse Contact Phone: +1.8003337680 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS63.WORLDNIC.COM Name Server: NS64.WORLDNIC.COM DNSSEC: unsigned >>> Last update of whois database: 2021-12-23T07:27:59Z <<< |